Research programme: fms-like tyrosine kinase 3 inhibitors - Antisoma/Johns HopkinsAlternative Names: DCAMs - Antisoma
Latest Information Update: 15 Jun 2011
At a glance
- Originator Johns Hopkins University
- Developer Antisoma
- Class Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders
Highest Development Phases
- Discontinued Autoimmune disorders